Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
 

ISPOR Seventh Annual European Congress

Contributed Poster Presentations Session II


BLOOD-RELATED DISEASES/DISORDERS 
 

Cost Studies

PBR1

COST OF KALIUM SUPPLEMENTATION WITH KALIPOZ PROLONGATUM OR KALDYUM FROM PAYER PERSPECTIVE IN POLAND
Kawalec P1, Glogowski C2, Krzyzanowska A3
1 Jagiellonian University, Kraków, Malopolska, Poland; 2 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland; 3 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland, WARSZAWA, Poland

PBR2

ECONOMIC IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH HEMOPHILIA A
Chung KC1, Mueller L2
1Baxter BioScience, Westlake Village, CA, USA; 2 MORE Baxter Bioscience, Deerfield, IL, USA

PBR3

ECONOMIC MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM): VALUE OF POTENTIAL VIRAL TRANSMISSION REDUCTION DUE TO PLASMA/ALBUMIN-FREE FORMULATION
Sclar DA1, Skaer TL1, Robison LM1, Evans MA1, Chung KC2, Poulios NS2
1 Washington State University, Pullman, WA, USA; 2 Baxter BioScience, Westlake Village, CA, USA

PBR4

COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN JAPAN
Staginnus U1, Russell S2, Corash LM3
1 Premor Associates, New York, NY, USA; 2 Premor Associates, Madrid, Spain; 3 Cerus Corporation, Concord, CA, USA

PBR5

COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH FONDAPARINUX IN MAJOR ORTHOPAEDIC SURGERY IN SWITZERLAND
Sendi P1, Leuppi JD2
1 Institute for Clinical Epidemiology, University Hospital, Basel, Switzerland; 2 Peumology, University Hospital, Basel, BS, Switzerland

PBR6

ISAM:INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT. THE ITALIAN EXPERIENCE
Attinà G1, Baudo F2, Lopatriello S3, Pengo V4, Poli D5
1 AstraZeneca, Milano, Italy; 2 Ospedale Niguarda-Cà granda-, Milano, Italy; 3 Pbe Consulting S.r.L, Verona, Italy; 4 Università di Padova, Padova, Italy; 5 Azienda Ospedaliera Careggi, Firenze, Italy

Quality of Life/Utility/Preference Studies

PBR8

PHYSICIANS’ AND PHARMACISTS’ PREFERENCES FOR HEMOPHILIA TREATMENT EVALUATED BY CONJOINT ANALYSIS
Scalone L1, Monzini MS1, Villa M2, Gringeri A3, Mannucci PM3, Mantovani LG1
1 University of Milan, Milan, Italy; 2 National Research Council – Institute of Biomedical Technologies, Segrate (Milano), Italy; 3 University of Milan and IRCCS Maggiore Hospital, Milan, Italy

PBR9

ASSESSING HEALTH-RELATED QUALITY OF LIFE IN ROMANIAN HAEMOPHILIACS
Mihailov D1, Lippert BM2, Serban M3
1 Children’s Hospital, Timis, Romania; 2 MERG GmbH, Medical Economics Research Group, Munich, Germany; 3 University of Medicine and Pharmacy “Victor Babes”, Timis, Romania

PBR10

ESTABLISHING HEMOPHILIA PATIENTS’ PREFERENCES IN PROPHYLAXIS: A CONJOINT ANALYSIS PILOT STUDY
Monzini MS1, Gringeri A2, Scalone L1, Villa M3, Mannucci PM2, Mantovani LG1
1 University of Milan, Milan, Italy; 2 University of Milan and IRCCS Maggiore Hospital, Milan, Italy; 3 National Research Council – Institute of Biomedical Technologies, Segrate (Milano), Italy

PBR11

QUALITY OF LIFE IS ASSOCIATED TO ORTHOPEDIC STATUS IN HEMOPHILIACS WITH INHIBITORS
Scalone L1, Gringeri A2, Mannucci PM3, Mantovani LG1
1 Center of Pharmacoeconomics, University of Milan, Milan, Italy; 2 Department Internal Medicine Maggiore Hospital, University of Milan, Milan, Italy; 3 University of Milan, Milan, Italy

PBR12

CLINICAL AND SOCIO-DEMOGRAPHIC CHARACTERISTICS INFLUENCE PATIENTS’ PREFERENCES TOWARDS HEMOPHILIA TREATMENT
Monzini MS1, Gringeri A2, Scalone L1, Mannucci PM2, Mantovani LG1, Villa M3
1 University of Milan, Milan, Italy; 2 University of Milan and IRCCS Maggiore Hospital, Milan, Italy; 3 National Research Council – Institute of Biomedical Technologies, Segrate (Milano), Italy

 

DIABETES
 

Clinical Outcomes Studies

PDB1

ASSOCIATION OF PATIENTS’ KNOWLEDGE AND ADHERENCE TO MEDICAL ADVICE TO GLYCAEMIC CONTROL IN THE MANAGEMENT OF DIABETES MELLITUS
Lee VW, Sin KK, Yung MS, Li MK, Chan TY
The Chinese University of Hong Kong, Shatin, Hong Kong

Cost Studies

PDB2

EVALUATION OF IMPROVED UTILITY ESTIMATES IN COST EFFECTIVENESS ANALYSIS OF MULTIPLE COMPLICATIONS IN TYPE-2 DIABETES
McEwan P1, Peters JR2, Currie CJ2
1 University Hospital of Wales, Cardiff, Wales, UK; 2 Cardiff Research Consortium, Cardiff, Wales, UK

PDB3

COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UK
Smith I1, Palmer AJ2, Roze S2, Kennedy-Martin T1
1 Novo Nordisk UK, Crawley, UK; 2 CORE Center for Outcomes Research, Binningen/Basel, Switzerland

PDB4

THE DIABETES TYPE-2 COST PREDICTORS
Niewada M1, Glogowski C2, Latek M3, Pietrasik A4, Kamiñski B3, Gierczynski J2, Krzyzanowska A2
1 Medical University of Warsaw, Warsaw, Poland; 2 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland; 3 Warsaw School of Economics, Warsaw, Poland; 4 Medical University of Warsaw, Department of Cardiology, Warsaw, Poland

PDB5

COMMUNITY EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN GERMANY
Häussler B1, Berger U1, Mast O2
1 IGES Institut für Gesundheits- u. Sozialforschung, Berlin, Germany; 2 Hestia Health Care GmbH

PDB6

THE COST OF TYPE-2 DIABETES IN UKRAINE
Zaliska ON, Boyko AI
Lviv state medical university, Lviv, Ukraine

PDB7

LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK SETTINGS.
Lammert M1, Palmer AJ2, Roze S2, Minshall ME3, Valentine WJ2, Nicklasson L4
1 Novo Nordisk A/S, Bagsvaerd, Denmark; 2 CORE Center for Outcomes Research, Binningen/Basel, Switzerland; 3 CORE-USA, Fishers, IN, USA; 4 Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ, USA

PDB8

WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
Pirk O1, Ratzmann KP2, Carels J3, Bramlage P4, Kirch W4
1 Fricke & Pirk GmbH, Nuremberg, Germany; 2 Diabetische Schwerpunktpraxis, Berlin, Germany; 3 Sanofi-Synthelabo, Berlin, Germany; 4 Medizinische Fakultaet Carl Gustav Carus der Technischen Universitaet Dresden, Dresden, Germany

PDB9

THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS
Tilden D1, Stynes G1, Swift M2, Cockle S1, Haycox A3, Aristides M1
1 M-TAG Limited, Hammersmith, UK; 2 Takeda UK Limited, High Wycombe, UK; 3 University of Liverpool, Liverpool, UK

PDB10

THE COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLAND
Stynes G1, Tilden D1, Swift M2, Cockle S1, Haycox A3, Aristides M1
1 M-TAG Limited, Hammersmith, UK; 2 Takeda UK Limited, High Wycombe, UK; 3 University of Liverpool, Liverpool, UK

PDB11

PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA
Suntsov YI, Dedov II, Komarova VP, Vedeneeva LF
Endocrinology Research Center, Moscow, Russia

PDB12

COSTS OF TYPE-2 DIABETES MELLITUS: A COMPARISON BETWEEN DIABETIC AND NON-DIABETIC SUBJECTS
Perelli Cippo P, Scalone L, Mantovani LG
University of Milan, Milan, Italy

PDB13

ECONOMIC EVALUATION OF THE STEPPED VERSUS ORDINARY CARE FOR PREVENTION OF TYPE-2 DIABETES IN THE JDPP: JAPAN DIABETES PREVENTION PROGRAM
Yanagisawa S1, Shimaya M1, Nakahara N1, Kamae I1, Kuzuya H2
1 Kobe University, Kobe, Japan; 2 National Hospital Organization Kyoto Medical Center, Kyoto, Japan

PDB14

COST-EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE PERSPECTIVE
Schramm W1, Neeser K2, Mast O2, Lübben G3, Lütke A4
1 Eumedes, Krailling, Germany; 2 IMIB – Institute for Medical Informatics and Biostatistics, Basel, Switzerland; 3 Takeda Pharma GmbH, Aachen, Germany; 4 Med. In. Form, Scharbeutz, Germany

PDB15

A COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2 DIABETES PATIENTS FROM IMMEDIATE-RELEASE METFORMIN (GLUCOPHAGE®) TO A NEW EXTENDED-RELEASE FORMULATION OF METFORMIN (GLUCOPHAGE®XR)
Renaudin C1, Roze S2, Valentine WJ2, Palmer AJ2
1 Merck Santé, Lyon, France; 2 CORE Center for Outcomes Research, Binningen/Basel, Switzerland

PDB16

EFFECT OF PATIENT EDUCATION IN TYPE-2 DIABETES OVER 10 YEARS BASED ON A PROSPECTIVE DIABETES MODEL IN THE PROVINCE OF STYRIA, AUSTRIA
Habacher W1, Palmer AJ2, Pieber TR1, Rakovac I1, Fritz C1, Gfrerer R1, Roze S2
1 Joanneum Research, Graz, Austria; 2 CORE Center for Outcomes Research, Binningen/Basel, Switzerland

PDB17

ABSOLUTE AND INCREMENTAL EFFECTS OF THERAPY-SWITCHING THRESHOLDS ON THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESE TYPE-2 DIABETES PATIENTS IN GERMANY
Shearer A1, Bagust A1, Schoeffski O2, Liebl A3, Goertz A4
1 University of York, York, UK; 2 University Erlangen-Nuremberg, Nuremberg, Germany; 3 Diabetes Stoffwechselzentrum Tegernsee, Rottach-Egern, Germany; 4 GlaxoSmithKline, Munich, Germany

PDB18

SEARCHING FOR DIABETES MELLITUS (DM) IN PRIMARY CARE – IT IS GOOD VALUE-FOR-MONEY IN POLAND? (COST OF DIAGNOSING DIABETES MELLITUS IN PRIMARY CARE CONDITION IN POLAND)
Sieradzki J1, Faluta T2, Czech M2, Szczepañski M2, Wilkins A2, Pachocki R2
1 Jagiellonian University in Krakow, Krakow, Poland; 2 Servier Polska, Warsaw, Poland

PDB19

COST OF HOSPITAL ADMISSIONS FOR CARDIOVASCULAR DISEASE OVER FIVE YEARS IN PATIENTS WITH DIABETES MELLITUS
O’Brien JA, Duran P, Pitoniak-Morse CA, Caro JJ
Caro Research Institute, Concord, MA, USA

PDB20

COST AND OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE HONG SON, THAILAND
Ploylearmsang C1, Thakamphu L2
1 Mahasarakham University, Mahasarakham, Mahasarakham, Thailand; 2 Lampang Provincial Public Health Office, Lampang, Lampang, Thailand

PDB21

ECONOMIC VALUE OF ACARBOSE TREATMENT IN PERSONS WITH IMPAIRED GLUCOSE TOLERANCE (IGT) FOR THE GERMAN HEALTH CARE SYSTEM
Evers T1, Lüddeke HJ2, Liebl A3, Kotowa W4, Maclaine G5
1 Bayer Vital GmbH, Leverkusen, Germany; 2 Diabetische Schwerpunktpraxis, Munich, Germany; 3 Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany; 4 Fricke & Pirk GmbH, Nuremberg, Germany; 5 Bayer plc, Uxbridge, UK

PDB22

COST-EFFECTIVENESS ANALYSIS OF THE DIABETES PREVENTION PROGRAM IN A SPANISH SETTING
Palmer AJ1, Roze S1, Valentine WJ1, Renaudin C2
1 CORE Center for Outcomes Research, Binningen/Basel, Switzerland; 2 Merck Santé, Lyon, France

PDB23 COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED GLUCOSE TOLERANCE IN SWEDEN
Quilici S1, MacLaine G2, Hutka M1, Chancellor J1, McGuire A3
1 Innovus Research (UK) Ltd, High Wycombe, UK; 2 Bayer plc, Uxbridge, UK; 3 London School of Economics, London, UK
PDB34

A PHARMACOECONOMIC ANALYSIS OF THE USE OF AN INTENSIVE STRATEGY FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 (DM T2)

Smirnova OM1, Komarova VP2
1 Endocrinology Research Center, Moscow, Russia; 2 Aventis Pharma, Moscow, Russia

Quality of Life/Utility/Preference Studies

PDB24

CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN
Sadri H, MacKeigan L, Einarson TR, Leiter LA
University of Toronto, Toronto, ON, Canada

PDB25

QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS
Perelli Cippo P, Scalone L, Micheletti S, Mantovani LG
University of Milan, Milan, Italy

PDB26

THE IMPACT OF VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND WITHOUT TYPE-2 DIABETES
Currie CJ1, Peters JR1, Morrissey M1, Bergenheim K2, McEwan P3
1 Cardiff Research Consortium, Cardiff, Wales, UK; 2 AstraZeneca, Molndal, Sweden; 3 University Hospital of Wales, Cardiff, Wales, UK

Health Policy Studies

PDB27

A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT: THE CO-ORDINATED DIABETES HEALTHCARE NETWORK
Da Costa E1, Jasso Mosqueda G2, Lemasson H2, Roche B1, Guerraoui A1, Aguilera D1, Chicoye A3
1 Centre hospitalier de Vichy, Vichy, Auvergne, France; 2 AREMIS Consultants, Member of Aegisnet, Neuilly Sur Seine, Ile de France, France; 3 Aremis Consultants, Member of Aegisnet

PDB28

VALIDATION OF ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS: THE VIEWS OF PRIMARY CARE PHYSICIANS
Gutierrez L1, Magaz S1, Badia X2
1 Health Outcomes Policy and Economics, Barcelona, Spain; 2 Health Outcomes Research Europe Group, Barcelona, Spain

PDB29

THERAPY CHANGE AND PROGRESSION TO INSULIN USE AMONG TYPE-2 DIABETIC PATIENTS NEWLY TREATED WITH SULFONYLUREA (SU) OR METFORMIN (MF) MONOTHERAPY
Kerasidou O1, Yin D2, Lyu R2
1 The University of Sheffield, Sheffield, UK; 2 Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB30

DRUG UTILIZATION OF GLITAZONES IN ITALY
Arpinelli F, Visona G
GlaxoSmithKline S.p.A, Verona, Italy

PDB31

COMPARISON OF BLOOD PRESSURE AND ATTRIBUTABLE HEALTHCARE COSTS BY DIHYDROPYRIDINE VS NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INITIATED FOR HYPERTENSION IN DIABETES MELLITUS PATIENTS, AND MONITORING OF RENAL PARAMETERS
Barron JJ, Al-Zakwani IS, Iarocci TP, Groesbeck JM
HealthCore, Inc, Wilmington, DE, USA

PDB32

LONG-TERM DIABETES COMPLICATIONS: INFLUENCE OF DELAY IN STARTING INTENSIFIED THERAPY AND OF PATIENT RATES TREATED TO TARGET A1C. ANALYSES WITH THE DIABETES MELLITUS MODEL (DMM)
Bergemann R1, Huppertz E2, Mueller E1, Maxion-Bergemann S1
1 Analytica International, Loerrach, Germany; 2 Aventis Pharma Deutschland GmbH, Bad Soden, Germany

Methods

PDB33

EAGLE –DIABETES MODEL: BASIC FEATURES AND INTERNAL VALIDATION OF SIMULATING LONG-TERM DIABETIC OUTCOMES AND RELATED COSTS
Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Bergemann R
Analytica International, Loerrach, Germany

 

EYE, EAR & SKIN DISEASES/DISORDERS 

Clinical Outcomes Studies

PES1

ASSOCIATION BETWEEN DIMINISHED ACTIVITY OF DAILY LIVING AND VISUAL IMPAIRMENT IN SUBJECTS LIVING IN THE COMMUNITY: RESULTS FROM A FRENCH NATIONAL SURVEY
Brézin A1, Lafuma A2, Fagnani F2, Mesbah M3, Berdeaux G4
1 Hopital Cochin, Paris, France; 2 Cemka, Bourg-La-Reine, France; 3 Université de Bretagne-Sud, Vannes, France; 4 Alcon, Rueil-Malmaison, France

PES2

ASSOCIATION BETWEEN MORTALITY AND VISUAL IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL SURVEY
Brézin A1, Lafuma A2, Fagnani F2, Mesbah M3, Bordeaux G4
1 Hopital Cochin, Paris, France; 2 Cemka, Bourg-La-Reine, France; 3 Université de Bretagne-Sud, Vannes, France; 4 Alcon, Rueil-Malmaison, France

PES3

ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS. THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY OPEN ANGLE GLAUCOMA (POAG) AND OCULAR HYPERTENSION (OH) IN POLAND
Walczak J1, Pajor A1, Kaczor M1, Wcislo J2
1 Arcana Institute, Krakow, Poland; 2 Pfizer, Warsaw, Poland

PES4

EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE VARIATIONS ON THERAPEUTIC DECISION MAKING: A MODELING APPROACH BASED ON A RANDOMIZED CLINICAL TRIAL
Dubiner HB1, Berdeaux G2
1 Clayton eye center, Morrow, GA, USA; 2 Alcon, Rueil-Malmaison, France

Cost Studies

PES5

A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pfizer S.A, Alcobendas, Madrid, Spain

PES6

COST EFFECTIVENESS OF LATANOPROST IN FIRST LINE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN THE UK
Gosden T1, Costello S2, Orme ME2, Howard P2, Dooley JA1
1 Pfizer Ltd, Tadworth, UK; 2 Heron Evidence Development, Letchworth Garden City, UK

PES7

A PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS WITH GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pfizer S.A, Alcobendas, Madrid, Spain

PES8

RESOURCE UTILIZATION OF END-STAGE GLAUCOMA PATIENTS RECEIVING LOW VISION CARE: A US MULTI-SITE RETROSPECTIVE STUDY
Williams RT1, O’Connell WF2, Walt J3, Siegartel LR4, Katz LM4, Doyle JJ4
1 Deicke Center for Visual Rehabilitation, Wheaton, IL, USA; 2 State College of Optometry, State University of New York, New York, NY, USA; 3 Allergan Inc. USA, Irvine, CA, USA; 4 Analytica International, New York, NY, USA

PES9

PREVALENCE OF FRACTURES AND DEPRESSION AND THEIR ASSOCIATION WITH BLINDNESS IN A MEDICARE POPULATION WITH PRIMARY OPEN-ANGLE GLAUCOMA: AN EXAMINATION OF BLINDNESS-RELATED COMORBIDITIES AND THEIR COSTS
Spalding JR1, Coleman A2, Fei Y2, Buchholz P3, Globe D4
1 University of Southern California, School of Pharmacy, Los Angeles, CA, USA; 2 David Geffen School of Medicine, Los Angeles, CA, USA; 3 Allergan R&D Europe, Ettlingen, Germany; 4 University of Southern California, Los Angeles, CA, USA

PES10

A NATION-WIDE ESTIMATE OF NON-MEDICAL SOCIO-ECONOMIC CONSEQUENCES ATTRIBUTABLE TO VISUAL IMPAIRMENT IN FRANCE: A SOCIETAL PERSPECTIVE
Lafuma A1, Brézin A2, Fagnani F1, Mesbah M3, Berdeaux G4
1 Cemka, Bourg-La-Reine, France; 2 Hopital Cochin, Paris, France; 3 Université de Bretagne-Sud, Vannes, France; 4 Alcon, Rueil-Malmaison, France

PES11

ESTIMATION OF NATIONWIDE COSTS OF ANNUAL ASSISTANCE ATTRIBUTABLE TO VISUAL IMPAIRMENT, FROM AN ACTIVITY OF DAILY LIVING QUESTIONNAIRE
Berdeaux G1, Lafuma A2, Mimaud V2
1 Alcon, Rueil-Malmaison, France; 2 CEMKA, Bourg la Reine, France

PES12

NON-MEDICAL COSTS RELATED TO VISUAL IMPAIRMENT IN FOUR EUROPEAN COUNTRIES (FRANCE, GERMANY, ITALY AND THE UK)
Lafuma A1, Lopatriello S2, Hieke K3, Hutchinson J4, Mimaud V1, Berdeaux G5
1 CEMKA, Bourg la Reine, France; 2 PBE-Consulting, Verona, Italy; 3 Neos Health, Binningen, Switzerland; 4 Fourth Hurdle Consulting Ltd, London, UK; 5 Alcon France SA, Rueil-Malmaison, France

PES13

A COST MINIMISATION ANALYSIS OF CUSTOM PAK® FOR CATARACT SURGERY
Lafuma A1, Smith AF2
1 CEMKA, Bourg la Reine, France; 2 University of Oxford, Oxford, UK

PES26

ANALYSIS OF RUSSIAN PHARMACEUTICAL MARKET OF ANTI-GLAUCOMA MEDICINES IN THE PERIOD 2000-2003

Kuroyedov AV
Mandryka 2nd Central Military Clinical Hospital, Moscow, WA, Russia


Quality of Life/Utility/Preference Studies

PES14

RESPONSIVENESS OF SELF-REPORTED VISUAL FUNCTIONING IN AGE –RELATED MACULAR DEGENERATION (AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED TRIAL OF LUCENTIS™ (RANIBIZUMAB; RHUFAB V2)
Globe D1, Tonnu IQ1, Chang TS1, Fine J2
1 University of Southern California, Los Angeles, CA, USA; 2 Genentech, Inc, South San Francisco, CA, USA

PES15

IMPACT OF ATOPIC DERMATITIS ON PARENTΨS QUALITY OF LIFE AND USE OF DIRECT RESOURCES IN PATIENTS BETWEEN 2 AND 12 YEARS OLD. DAES STUDY
Espinosa C1, García A2, García-Patos V3, Hachero JG4, Polanco I5, Rodrigo C6, Zambrano A7, Figueras M1, Díaz JM1
1 Novartis Farmacéutica S.A, Barcelona, Spain; 2 Hospital de la Princesa, Madrid, Spain; 3 Hospital Vall D’Hebrón, Barcelona, Spain; 4 Hospital Virgen de la Macarena, Sevilla, Spain; 5 Hospital La Paz, Madrid, Spain; 6 Hospital Germans Trias I Pujol, Barcelona, Spain; 7 Hospital Niño Jesús, Madrid, Spain

PES16

SCALING PROPERTIES OF THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
McKenna SP, Meads DM, Doward LC
Galen Research, Manchester, UK

PES17

LIVING WITH A DERMATOSIS: A NATIONAL SURVEY OF QUALITY OF LIFE IN BELGIUM
Lambert J1, De la Brassinne M1, Myon E2, Martin N3, Monnier F4, Weckx H4, Taieb C2
1 Royal Belgium Society of Dermatology, Brussels, Belgium; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France; 3 IRPF, Boulogne-Billancourt, France; 4 AVENE Dermatological Laboratories, Brussels, Belgium

PES18

INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)
McKenna SP1, Meads DM1, Backhouse ME2
1 Galen Research, Manchester, UK; 2 Novartis Pharma AG, Basel, Switzerland

PES19

SENSITIVE SKIN: QUALITY OF LIFE IMPACT
Misery L1, Myon E2, Martin N2, Verriere F3, Nocera T3, Taieb C2
1 Dermatological Clinic, Brest, France; 2 IRPF, Boulogne-Billancourt, France; 3 Avene Dermatological Laboratories, Lavaur, France

PES20

SUNBURNS AND QUALITY OF LIFE
Guitera P1, Dubertret L1, Myon E2, Nocera T3, Perez N3, Martin N2, Taieb C2
1 Hopital Saint Louis, Paris, France; 2 IRPF, Boulogne-Billancourt, France; 3 Avene Dermatological Laboratories, Lavaur, France

PES21

HAIR LOSS, QUALITY OF LIFE IMPACT
Taieb C1, Macy G2, Sibaud V2, Martin N1, Myon E1
1 IRPF, Boulogne-Billancourt, France; 2 DUCRAY Dermatological Laboratories, Lavaur, France

PES22

HAIR LOSS, EPIDEMIOLOGICAL APPROACH
Taieb C1, Macy G2, Sibaud V2, Martin N1, Myon E1
1 IRPF, Boulogne-Billancourt, France; 2 DUCRAY Dermatological Laboratories, Lavaur, France


Health Policy Studies

PES23

SUN SENSITIVITY AND PERSONAL BEHAVIOURS
Guitera P1, Dubertret L1, Myon E2, Perez N3, Nocera T3, Martin N2, Taieb C2
1 Hopital Saint Louis, Paris, France; 2 IRPF, Boulogne-Billancourt, France; 3 Avene Dermatological Laboratories, Lavaur, France

PES24

IMPACTED CERUMEN: A LITERATURE REVIEW
Guest JF1, Greener MJ1, Smith AF2
1 Catalyst Health Economics Consultants, Middlesex, UK; 2 University of Oxford, Oxford, UK


Methods

PES25

ASSOCIATION BETWEEN VITAMIN SUPPLEMENTS USAGE AND PRESENCE OF AGE-RELATED MACULAR DEGENERATION IN A LATINO POPULATION ADJUSTING FOR SELECTION BIAS USING PROPENSITY SCORES
Bonnet PO1, Globe D1, Varma R2, Johnson KA1
1 University of Southern California, School of Pharmacy, Los Angeles, CA, USA; 2 University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

 

GASTROINTESTINAL DISEASES/DISORDERS
 

Cost Studies

PGI1

ECONOMIC EVALUATION OF ON-DEMAND MAINTENANCE THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE – A MONTE-CARLO ANALYSIS FOR ITALY
Hughes DA1, Marchetti M2, Colombo GL3
1 University of Liverpool, Liverpool, Merseyside, UK; 2 IRCCS Policlinico San Matteo, Pavia, Italy; 3 S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy

PGI2

THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING ‘TEST-AND-TREAT’ WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY
Klok RM1, Arents NL2, De Vries R1, Thijs JC3, Brouwers JR1, Kleibeuker JH2, Postma MJ1
1 University of Groningen, Groningen, Groningen, Netherlands; 2 University Hospital Groningen, Groningen, Groningen, Netherlands; 3 Bethesda Hospital, Hoogeveen, Drenthe, Netherlands

PGI3

COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY
Gross M1, Braun S2, Reitberger U2, Spannheimer A2
1 Internistische Klinik Dr. Mueller, Munich, Germany; 2 Kendle International Inc, Munich, Germany

PGI4

USE OF CAPSULE ENDOSCOPY IN DIAGNOSING OBSCURE GASTROINTESTINAL BLEEDING: COST–EFFECTIVENESS EVALUATION FROM A EUROPEAN PERSPECTIVE
Mueller E, Schwander B, Bergemann R
Analytica International, Loerrach, Germany

PGI5

COSTS BENEFITS WITH ESOMEPRAZOLE 20MG ‘ON-DEMAND’ TREATMENT IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN BELGIUM
Louis E1, Urbain D2, Deltenre M3, Vandenhoven G4, Duquenne V4, Schockaert B4
1 Ulg, Liège, Belgium; 2 AZ VUB, Brussel; 3 ULB, Bruxelles, Belgium; 4 NV AstraZeneca SA, Brussels, Belgium

PGI6

ECONOMIC EVALUATION OF RABEPRAZOLE VS. OMEPRAZOLE IN THE CURATIVE TREATMENT OF REFLUX OESOPHAGITIS
Colombo GL1, Caraglia M2, Casalini S2, Nardini P2
1 S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy; 2 Janssen-Cilag SpA, Latina, Italy

PGI7

COST BENEFIT ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS
Yang MC, Lai GL
National Taiwan University, Taipei, Taiwan

PGI8

PHARMACOECONOMIC ASPECTS OF CROHN´S DISEASE IN SLOVAKIA
Bielik J1, Hlista M2, Èernok S3
1 Slovak Society for Pharmacoeconomics, Nové Mesto nad Váhom, Slovak Republic; 2 Hospital Trenèín, Trenèín, Slovak Republic; 3 Hospital Nové Mesto nad Váhom, Nové Mesto nad Váhom, Slovak Republic


Quality of Life/Utility/Preference Studies

PGI9

IS HELICOBACTER PYLORI “TEST AND TREAT” A COST-EFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A HIGH PREVALENCE OF H. PYLORI INFECTION
You JH, Wong PL, Wu JC
The Chinese University of Hong Kong, Shatin, N.T, Hong Kong

PGI10

HEALTH RELATED QUALITY OF LIFE AMONG POLISH GASTROESOPHAGEAL REFLUX DISEASE PATIENTS
Kamiñski B1, Niewada M2, Regu³a J3, Kowalik E4
1 Warsaw School of Economics, Warsaw, Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3 Institute of Oncology, Warsaw, Mazowieckie, Poland; 4 Institute of Cardiology, Warsaw, Poland

PGI11

PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH AND WITHOUT GI COMPLICATIONS
Kleinman L1, Bahner U2, Faull R3, Walker R4, Prasad R5, Ambuehl P6, Machnicki G7, Margolis MK1
1 Medtap International, Seattle, WA, USA; 2 KfH Kuratorium fur Dialyse un Nierentrasnplantation, Wurzburg, Germany; 3 Royal Adelaide Hospital, Adelaide, Australia; 4 The Royal Melbourne Hospital, Parkville, Australia; 5 St. Michael’s Hospital, Toronto, Ontario, Canada; 6 University Hospital Zurich, Zurich, Switzerland; 7 Novartis Pharma AG, Basel, Switzerland

PGI12

HEALTH-RELATED QUALITY OF LIFE AND PATIENT SELF-PERCEIVED HEALTH STATUS IN IBS
Ten Berg MJ1, Goettsch WG1, Van den Boom G2, Smout AJPM3, Herings RMC1
1 PHARMO Institute, Utrecht, Netherlands; 2 Novartis Pharma B.V, Arnhem, Netherlands; 3 University Medical Centre, Utrecht, Netherlands

PGI13

EFFECT OF TEGASEROD IN WOMEN WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN SOUTH AFRICA
Schneider HR1, Goncalves J2,
1Milpark Hospital, Parktown, South Africa; 2Novartis, Johannesburg, South Africa


Methods

PGI14

COST-EFFECTIVENESS EVALUATION FOR A NEW DIAGNOSTIC TEST CONSIDERING ALSO COSTS FOR FALSE NEGATIVE AND FALSE POSITIVE DIAGNOSES AT VARIOUS PREVALENCE RATES
Mueller E, Schwander B, Bergemann R
Analytica International, Loerrach, Germany

 

INFECTION

 

Clinical Outcomes Studies

PIN1

CLINICAL PRACTICE GUIDELINE EVALUATION: NEONATAL INFECTION WITH MATERNAL HISTORY OF PREMATURE RUPTURE OF MEMBRANE (PROM)
Srijariya W1, Ratanakorn W2, Chamnanwanakij S2, Saeng-arun P2
1 Mahidol University, Bangkok, Thailand; 2 Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand


Cost Studies

PIN2

COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED METHICILLIN–RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL PNEUMONIA IN GERMANY
Grünewald T1, De Cock E2, Sorensen S3, Baker T3, Resch A4, Hardewig J4, Duttagupta S5
1 Städt. Klinikum St. Georg, Leipzig, Germany; 2 MEDTAP International Inc, London, UK; 3 MEDTAP International Inc, Bethesda, MD, USA; 4 Pfizer GmBH, Karlsuhe, Germany; 5 Pfizer Inc, New York, NY, USA

PIN3

LINEZOLID FOR THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS – A COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN: EVIDENCE FROM A MULTINATIONAL CLINICAL TRIAL
Sorensen SV1, Hollenbeak CS1, Baker TM1, Resch A2, Duttagupta S3
1 MEDTAP International Inc, Bethesda, MD, USA; 2 Pfizer GmBH, Karlsruhe, Germany; 3 Pfizer Inc, New York, NY, USA

PIN4

COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN SPAIN
Grau S1, Álvarez-Lerma F2, De la Fuente S3, Neipp R3, Rubio-Terres C4
1 Hospital del Mar, Barcelona, Spain; 2 Hospital del Mar; 3 Pfizer S.A. Spain, Madrid, Spain; 4 HERO Consulting

PIN5

MEASURING RESOURCE USE AND DIRECT COSTS IN PATIENTS WITH HEPATITIS C VIRUS MANAGED IN A GASTROENTEROLOGY AND HEPATOLOGY SERVICE
Herdman M1, Casanovas T2, Rodriguez Fariña E2, Rodriguez T3, Ibarz R3, Casais L2
1 3D Health Research, Barcelona, Barcelona, Spain; 2 University Hospital of Bellvitge; 3 3D Health Research

PIN6

CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPE-SPECIFIC GUIDELINES
Siebert U1, Sroczynski G1, Aidelsburger P2, Rossol S3, Wasem J2, Manns MP4, McHutchison JG5, Wong JB6
1 Harvard Medical School, Boston, MA, USA; 2 University of Duisburg-Essen, Duisburg-Essen, Germany; 3 University of Mainz, Ruesselsheim, Germany; 4 Medical School of Hanover, Hanover, Germany; 5 Scripps Clinic, La Jolla, CA, USA; 6 Tufts University School of Medicine, Boston, MA, USA

PIN7

COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS. INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS
Rubio M1, Oppenheimer F2, Magaz S1, Badia X1
1 Health Outcomes Research Europe, Barcelona, Barcelona, Spain; 2 Hospital Clinic I Provincial de Barcelona, Barcelona, Spain

PIN8

ECONOMIC EVALUATION OF HIV TREATMENTS: THE I.CO.N.A. COHORT STUDY
Merito M1, Baio G2, Bonaccorsi A3, Pammolli F4, Riccaboni M4, Arici C5, D’Arminio Monforte A6, Pezzotti P7, Corsini D8
1 Sant’Anna School of Advanced Studies, Pisa, PI, Italy; 2 University of Florence, Florence, Italy, Italy; 3 Sant’Anna School of Advanced Studies, Italy; 4 University of Florence, Italy; 5 Ospedali Riuniti – Bergamo, Italy; 6 University of Milan, Italy; 7 Istituto Superiore di Sanità, Italy; 8 Informa srl, Italy

PIN9

COMPARING COSTS AND EFFECTIVENESS OF HAART TIMING IN HIV INFECTION: EVIDENCE FROM THE I.CO.N.A. COHORT (ON BEHALF OF THE I.CO.N.A. STUDY GROUP)
Merito M1, Pezzotti P2
1 Sant’Anna School of Advanced Studies, Pisa, PI, Italy; 2 Istituto Superiore di Sanità, Italy

PIN10

COST-EFFECTIVENESS OF EXPANDED HIV SCREENING OF BLOOD DONATIONS IN GHANA
Van Hulst M1, Vermande J2, Sagoe K3, Bos JM4, Postma MJ2
1 University of Groningen / Martini Hospital, Groningen, Groningen, Netherlands; 2 University of Groningen, Groningen, Groningen, Netherlands; 3 University of Ghana Medical School, Accra, Accra, Ghana; 4 The Netherlands Vaccine Institute, Bilthoven, Utrecht, Netherlands

PIN11

PHARMACOECONOMIC EVALUATION OF HERD PROTECTION FOR THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWITZERLAND
Ciuryla VT1, Siegartel LR2, Casciano R3
1 Wyeth, Collegeville, PA, USA; 2 Analytica International, New York, NY, USA; 3 Analytica International, Lörrach, Germany

PIN12

COST-EFFECTIVENESS OF UNIVERSAL PNEUMOCOCCAL VACCINATION FOR INFANTS IN ITALY
Marchetti M1, Colombo GL2
1 IRCCS Policlinico San Matteo, Pavia, Italy; 2 S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy

PIN13

ECONOMIC EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN GERMANY
Jansen J1, Kern W2, Resch A3
1 MAPI Values, Houten, Netherlands; 2 Albert-Ludwigs-Universität, Freiburg, Germany; 3 Pfizer GmbH, Karlsruhe, Germany

PIN14

CALCULATING THE COST OF WOUND CARE IN A COMMUNITY SETTING IN THE UK: AN EXAMPLE USING MODERN WOUND MANAGEMENT DRESSINGS
Orme ME1, Daniels S2
1 Heron Evidence Development, Letchworth Garden City, UK; 2 ConvaTec UK Ltd, Ickenham, Uxbridge, UK

PIN15

ACUTE ROTAVIRUS GASTROENTERITIS: BURDEN OF DISEASE AND COST OF ILLNESS AMONG YOUNG CHILDREN IN GERMANY
Hammerschmidt T, Gartner B
GlaxoSmithKline, Munich, Germany

PIN16

ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Decker-Burgard S1, Ehrnsperger M2, Eichmann FRW2, Huppertz E1, Kreyenberg K2, Reitberger U2, Roscher K1, Spannheimer A2
1 Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Germany; 2 Kendle International Inc, Munich, Germany

PIN17

THE COSTS OF SEVERE SEPSIS MANAGEMENT IN INTENSIVE CARE UNITS IN POLAND
Kübler A1, Kowalik E2, Niewada M3, Jakubczyk M4, Lis J5
1 Wrocaw Medical University, Wrocaw, Poland; 2 Institute of Cardiology, Warsaw, Poland; 3 Medical University of Warsaw, Warsaw, Poland; 4 Center for operations research and econometrics, Université catholique de Louvain, Louvain-la-Neuve, Belgium; 5 Eli Lilly, Warsaw, Poland

PIN18

ASSESSING THE COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS IN POLAND
Jakubczyk M1, Kowalik E2, Niewada M3, Kübler A4, Lis J5, Kamiñski B6
1 Center for operations research and econometrics, Université catholique de Louvain, Louvain-la-Neuve, Belgium; 2 Institute of Cardiology, Warsaw, Poland; 3 Medical University of Warsaw, Warsaw, Poland; 4 Wrocaw Medical University, Wrocaw, Poland; 5 Eli Lilly, Warsaw, Poland; 6 Warsaw School of Economics, Warsaw, Poland

PIN19

A COMPARISON OF COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK
Lewis GJ1, Green J2, Patel K2, Philips Z3
1 Roche Products Ltd, Welwyn Garden City, Herts, UK; 2 Hoffman La Roche, Nutley, NJ; 3 York University, York, UK

PIN20

COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND CASPOFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN
Domínguez-Gil Hurlé A1, Martín Herranz I2, García Vargas M3, Rejas J4
1 Department of Pharmacy, University Hospital at Salamanca, Salamanca, Salamanca, Spain; 2 Department of Pharmacy, Juan Canalejo Hospital, A Coruña, Spain; 3 Medical Unit, Euroclin Institute, Madrid, Spain; 4 Pfizer SA, Alcobendas, Madrid, Spain

PIN21

COST-BENEFIT ANALYSIS OF ANTI-INFLUENZA VACCINATION IN A PUBLIC HEALTH CARE UNIT
Colombo GL1, Ferro A2, Vinci M3, Zordan M2
1 S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy; 2 ULSS 17, Regione Veneto; 3 S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy

PIN22

MODELLING THE COST-EFFECTIVENESS OF ACTIVATED PROTEIN C (XIGRIS® ) TREATMENT OF SEPTIC PATIENTS IN INTENSIVE CARE UNITS IN HUNGARY
Hoffer G1, Csomós Á2, Kardos L1, Demeter J3, Homoki H4, Zaray L5
1 University of Debrecen, Debrecen, Hungary; 2 Markoth Ferenc County Hospital, Eger; 3 MD&B Ltd; 4 Lilly Hungaria Ltd; 5 Lilly Hungaria Ltd, Debrecen, Germany

PIN23

PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN YOUNGER THAN 3 YEARS IN GERMANY (PRI.DE) – ECONOMIC IMPACT OF COMMUNITY-ACQUIRED CASES TREATED BY OFFICE-BASED PEDIATRICIANS (PRIMARY CARE)
Ehlken B1, Berger K2, Ihorst G3, Petersen G4, Forster J5
1 MERG, Medical Economics Research Group, Munich, Germany; 2 MERG Medical Economics Research Group, Munich, Germany; 3 Institute for Medical Biometry and Medical Informatics, and Center for Clinical Trials, Freiburg, Germany; 4 Wyeth Pharma GmbH, Münster, Germany; 5 St. Josefskrankenhaus, Freiburg, Germany

PIN32

THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER

Maselli MA1, Scalone L2, Pezzolla F1, Demma I1, Mantovani LG2
1 Scientific Institute of Gastroenterology, Castellana Grotte (Bari), Italy; 2 Center of Pharmacoeconomics, University of Milan, Milan, Italy


Quality of Life/Utility/Preference Studies

PIN24

IMPROVEMENT IN PATIENT-REPORTED DEPRESSION IN HIV+ PATIENTS EXPERIENCING GRADE 2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR (PI)/NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH LOPINAVIR/RITONAVIR (LPV/R)
Luo MP, Shen Y, McMillan F, Sylte J, Ashraf T, Rode R
Abbott Laboratories, Abbott Park, IL, USA

PIN25

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE MEASURES IN HIV AND AIDS
Clayson DJ1, Wild DJ1, Quarterman P1, Coons SJ2, Duprat-Lomon I3, Kubin M4
1 Oxford Outcomes Ltd, Oxford, Oxon, UK; 2 The University of Arizona College of Pharmacy, Tucson, AZ, USA; 3 Bayer Pharma, Puteaux Cedex, Paris, France; 4 Bayer HealthCare, Wuppertal, Elberfeld, Germany

PIN26

VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
Taylor DC1, Norman GR2, Torrance G3, Thompson D1, Amorosi SL1, Asche CV4, Patel M4, Lavin B4, Ferguson B5
1 Innovus Research, Inc, Medford, MA, USA; 2 McMaster University, Hamilton, ON, Canada; 3 Innovus Research, Inc, Burlington, ON, Canada; 4 Aventis Pharmaceuticals, Bridgewater, NJ, USA; 5 University ENT Specialists, Inc, Pittsburgh, PA, USA

PIN27

WILLINGNESS TO PAY FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (TB) IN RURAL NEPAL: A CONTINGENT VALUATION STUDY
Paudel L1, Adhikari M1, Devkota N2
1 The University of Georgia, Athens, GA, USA; 2 Lousiana State University, Baton Rouge, LA, USA

PIN28

ASSESSMENT OF BODY CHANGES AND DISTRESS (ABCD) LIPODYSTROPHY QUESTIONNAIRE : CULTURAL ADAPTATION AND PSYCHOMETRIC VALIDATION IN FRENCH
Duracinsky M1, Sereni D2, Molina JM2, Acquadro C3, Wu A4, Chassany O5
1 Hopital de Bicetre, Le Kremlin-Bicetre, France; 2 Hopital Saint-Louis, Paris, France; 3 MAPI Research Institute, Lyon, France; 4 Johns Hopkins University, Baltimore, MD, USA; 5 Assistance Publique – Hopitaux de Paris, Paris, France

PIN28

FREQUENCY OF POTENTIAL DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL USE IN DUTCH HOSPITAL SETTINGS
Sturkenboom MC1, Goettsch WG2, Picelli G1, Herings RMC2
1 International Pharmacoepidemiology and Pharmacoeconomics Research Center, Desio, MI, Italy; 2 PHARMO Institute, Utrecht, Netherlands


Health Policy Studies

PIN29

COSTS AND EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS: DYNAMIC VERSUS STATIC MODELING
Welte R1, Postma MJ2, Leidl R3, Kretzschmar M4
1 GSF – National Research Center for Environment and Health, Neuherberg, Germany; 2 University of Groningen, Groningen, Netherlands; 3 Ludwig-Maximilians-University, Munich, Germany; 4 RIVM – National Institute of Public Health and the Environment, Bilthoven, 3720 BA, Netherlands

Methods

PIN29

ECONOMIC EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS IMPACT ON DECISION MAKING
Welte R1, Trotter C2, Edmunds J2, Postma MJ3, Beutels P4
1 GSF - National Research Center for Environment and Health, Neuherberg, Germany; 2 Health Protection Agency, London, UK; 3 University of Groningen, Groningen, Netherlands; 4 University of Sydney, Westmead, Australia

 

METHODS

 

PMC1

BOOTSTRAP CONFIDENCE INTERVALS FOR THE ANGULAR TRANSFORMED ICER: ARE MORE SOPHISTICATED METHODS THE BETTER CHOICE?
Schweikert B1, Reitmeir P2
1 Ludwig-Maximilians-University, Munich, Germany; 2 GSF- National Research Center for Environment and Health, Neuherberg, Germany

PMC2

A FRAMEWORK FOR HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMS.
Darbà J1, Albacar E2
1 Universitat de Barcelona, Barcelona, Spain; 2 Clinical Data Care, Barcelona, Spain

PMC3

ECONOMIC EVALUATION IN LATIN AMERICA

Crosbie G1, Pritchard C2
1 OHE-IFPMA Database Ltd, London, UK; 2 Office of Health Economics, London, UK

PMC4

CAN ECONOMIC EVALUATIONS BE MADE MORE TRANSFERABLE?
Drummond MF1, Boulenger SM2, Rice SJC3, Ulmann P4, Nixon J3, De Pouvourville G5
1 University of York, York, North Yorkshire, UK; 2 College des Economistes de la Sante, Paris, Paris, France; 3 University of York, YORK, North Yorkshire, UK; 4 CNAM/CES, Paris, Paris, France; 5 INSERM U 537, Le Kremlin-Bicêtre, France

PMC5

ARE THE BEST AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN ECONOMIC EVALUATIONS OF DRUG THERAPIES?
Drummond M1, Hanratty B2, Nixon J1, Christie J1
1 University of York, York, North Yorkshire, UK; 2 University of Liverpool, Liverpool, Liverpool, UK

PMC6

THE IMPORTANCE OF ACCOUNTING FOR THE PORTFOLIO EFFECTS IN COST EFFECTIVENESS ANALYSES
Bridges JFP
University of Heidelberg, Heidelberg, BW, Germany

PMC7

UNIQUE USES OF INSURANCE DATA RECORDS

Meyer J1, Crown WH2, Grina M1
1 Ingenix, Eden Prairie, MN, USA; 2 Ingenix, Auburndale, MA, USA

PMC8

OVER-THE-COUNTER PHENAZOPYRIDINE: AN ASSESSMENT OF CONSUMER KNOWLEDGE

Shi CW
University of California, San Diego, La Jolla, CA, USA

PMC9

HEALTH PROGRAM IMPACT EVALUATION USING OBSERVED AND EXPECTED TIME SERIES OF PHARMACEUTICAL CONSUMPTIONS
Menna A1, Marata AM1, Solfrini V2, Magrini N1
1 Local Health Authority, Modena, Modena, Italy; 2 Local Health Authority, Bologna, Italy

PMC10

ASP PLUS SIX PERCENT IN 2005-A CONCEPTUAL VIEW OF FUTURE PHYSICIAN PAYMENTS FOR DRUGS AND THEIR ADMINISTRATION IN THE OFFICE SETTING
Baker JJ
Resource Group, Ltd, Pickton, TX, USA

PMC11

COMPARING DIFFERENT APPROXIMATION METHODS FOR REMAINING LIFE EXPECTANCY IN DECISION TREES
Siebert U, Conrads FA
Harvard Medical School, Boston, MA, USA

PMC12

EVALUATING DRUG SAFETY USING STOCHASTIC SIMULATION MODELS
Maguire A1, Arellano FM2, Perez-Gutthan S1
1 Pfizer, Sant Cugat, Barcelona, Spain; 2 Risk Management Resources, Califon, NJ, USA

PMC13

DEVELOPING THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATIONS DATABASES (EURONHEED): THE ACTIVITIES OF ONE CENTRE TO FULFILL BOTH INTERNATIONAL AND LOCAL NEEDS
Redekop WK1, Van Nooten F1, Bouwmans C1, Rutten F2, Koopmanschap MA3
1 Institute of Health Policy and Management, Rotterdam, Netherlands; 2 Institute for Medical Technology Assessment, Rotterdam, Netherlands; 3 Erasmus Medical Centre, Rotterdam, Netherlands

PMC14

PERSONAL DRUG UTILIZATION REPORT (PDUR) - A CONTRIBUTION TO COST REDUCTION AND PATIENT EMPOWERMENT
Lentges N, Verheyen F, Hecke TL, Müller H
Techniker Krankenkasse, Hamburg, Germany

PMC15

WEIGHING DIAGNOSES IN EVALUATION STUDIES WITH AN APPLICATION TO SYNCOPE
Boer KR, Van Dijk N, Wieling W, Dijkgraaf MGW
Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

PMC16

ANNUAL BURDEN OF DRY EYE SYNDROME IN SIX EUROPEAN COUNTRIES
Clegg JP1, Guest JF1, Smith AF2
1 Catalyst Health Economics Consultants, Middlesex, United Kingdom; 2 University of Oxford, Oxford, United Kingdom

PMC17

THERE'S NO F IN UTILITY
Kind P
Outcomes Research Group, York, UK

PMC18

STATISTICAL ISSUES IN DISCRETE CHOICE MODELLING
Fitzgerald PE1, Aristides M2
1 M-TAG Pty Ltd, Chatswood West, New South Wales, Australia; 2 M-TAG Ltd, London, UK

PMC19

Withdrawn

PMC20

DEVELOPMENT OF A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN
Artes M1, Muñoz A1, Cobo JM2, Casas F3, Zaragoza S4, Cáceres M5
1 Adelphi Targis, Barcelona, Spain; 2 Danone, Barcelona, Spain; 3 Universidad de Girona, Girona, Spain; 4 Psyncro, Barcelona, Spain; 5 Hospital General de Catalunya, Catalunya, Spain

PMC21

AN EXPLORATION OF THE DISCREPANCIES BETWEEN HEALTH STATE VALUATIONS OF PATIENTS AND THE GENERAL POPULATION
Ratcliffe J, Brazier J, Palfreyman S, Michaels J
Sheffield University, Sheffield, UK

PMC22

REVIEW OF INSTRUMENTS MEASURING TREATMENT SATISFACTION WITH MEDICATION
Gandra SR1, Parasuraman B2, Lawrence LW1, Humble LJ1
1 The University of Louisiana at Monroe, Monroe, LA, USA; 2 AstraZeneca LP, Wilmington, DE, USA

PMC23

REVIEW AND ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN MEXICO

Bravo Ruiz ML1, Soto Molina H2, Guzmán Vasquez S3, Arreola Ornelas H2, Villasis MA2, Reynoso N N2, Rely K2, Garduño Espinosa J2
1 Secretaria de Salud, Mexico D.F, Mexico D.F, Mexico; 2 Instituto Mexicano Seguro Social, Mexico D.F, Mexico D.F, Mexico; 3 Universidad del Estado De México, Toluca, Estado de México, Mexico

 

MENTAL HEALTH

 

Clinical Outcomes Studies

PMH1

IMPACT OF WEIGHT GAIN ON TREATMENT EFFECTIVENESS WITH OLANZAPINE OR ARIPIPRAZOLE, CONSIDERING NON-ADHERENCE, RELAPSE AND COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN FINLAND
Ruppert A1, Muhonen T2, Sinkkonen T2
1 Bristol-Myers Squibb, Braine-l'Alleud, Belgium; 2 Bristol-Myers Squibb, Espoo, Finland

PMH2

GEO OBSERVATIONAL STUDY: 12 MONTH'S DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann FRW1, Reitberger U1, Clouth J2, Salize HJ3
1 Kendle International Inc, Munich, Germany; 2 Lilly Deutschland GmbH, Hamburg, Germany; 3 Zentralinstitut für Seelische Gesundheit, Mannheim, Germany


Cost Studies

PMH3

FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE: A TIME-TO-EVENT ANALYSIS
Adriaenssen I1, Rosillon D2, Mehnert A3, Price M4, Ingham M1
1 Janssen Pharmaceutica N.V, Beerse, Belgium; 2 SGS Biopharma S.A, Wavre, Belgium; 3 Janssen Cilag, Neuss, Germany; 4 Janssen-Cilag, High Wycombe, Buckinghamshire, UK

PMH4

THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER IN AUSTRALIA; A RETROSPECTIVE AUDIT
Crowley S1, Kulkarni J2, Arya D3, Fitzgerald P4, DeCastella A4, Meere S1
1 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia; 2 Alfred Psychiatry Research Centre and Monash University, Melbourne, VIC, Australia; 3 Fremantle Hospital and University of Western Australia, Perth, WA, Australia; 4 Alfred Psychiatry Research Centre, Melbourne, VIC, Australia

PMH5

FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED FROM PSYCHIATRIC HOSPITALS IN THE UK ON RISPERIDONE OR OLANZAPINE: A TIME-TO-EVENT ANALYSIS
Price M1, Rosillon D2, Ingham M3, Adriaenssen I3
1 Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 2 SGS Biopharma S.A, Wavre, Belgium; 3 Janssen Pharmaceutica N.V, Beerse, Belgium

PMH6

HEALTH EFFECTS AND HEALTH CARE RESOURCE UTILIZATION IN POLISH SCHIZOPHRENIC OUTPATIENTS INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL ANTIPSYCHOTIC MONOTHERAPY: ANALYSIS OF 12-MONTH DATA FROM SOHO STUDY
Orlewska E1, Lis J2, Debowska G2
1 Centre for Pharmacoeconomics, Warsaw, Poland; 2 Eli Lilly, Warsaw, Poland

PMH7

The ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY AN ELECTRONIC REGISTRY TO EVALUATE OUTCOMES DATA IN PATIENTS
Dominic Farmer1, Brecht Claerhout2, Angelika Mehnert3, Mike Ingham3, An Jacobs3 on behalf of the e-STAR study group
1IES, UK, 2Custodix NV, Belgium, 3Janssen Pharmaceutica, Health Economics, Belgium

PMH8

COSTS AND EFFECTS OF RISPERDAL CONSTA I IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN PORTUGAL
Heeg BM1, Buskens E1, Vaz Serra A2, Pacheco Palha A3, Marques Teixeira J4, Figueira L5, Jara J6, van Hout B1
1 PharMerit, Capelle a/d Ijssel, Netherlands; 2 Hospitais da Universidade de Coimbra, Coimbra, Portugal; 3 Hospital de Sao Joao, Oporto, Portugal; 4 Hospital de Conde Ferreira, Oporto, Portugal; 5 Hospital de Sante Maria, Lisbon, Portugal; 6 Hospital de Julio de Matos, Lisbon, Portugal

PMH9

A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UK
Hemels ME1, Toumi I1, Wade AG2
1 H. Lundbeck A/S, Paris, France; 2 CPS Research, Glasgow, UK

PMH10

ECONOMIC ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN NEW ZEALAND
Davies A1, Schrover R2, Crowley S2, Neville AM3
1 Solutions for Health Ltd, Auckland, New Zealand; 2 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia; 3 Pretium, Sydney, NSW, Australia

PMH11

PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN THE UK
Hemels ME1, Toumi I1, Wade AG2
1 H. Lundbeck A/S, Paris, France; 2 CPS Research, Glasgow, UK

PMH12

THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER IN THE UK
Beard SM1, Earnshaw SR2, Gaffney L1, Hogue SL3, Krishnan AA3
1 RTI Health Solutions, Manchester, UK; 2 RTI Health Solutions, Raleigh-Durham, NC, USA; 3 GlaxoSmithKline, Raleigh-Durham, NC, USA

PMH13

THE COST- EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER IN JAPAN
Nakahara N1, Kamae I2, Yanagisawa S2
1 Kobe University, Tokyo, Japan; 2 Kobe University, Kobe, Japan

PMH14

THE HEATLH –RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
Hakkaart L1, Zwirs B2, Buitelaar J3, Schulpen T2, Vlasveld L4, Bouwmans C1, Rutten F1, Veraart C5
1 Institute for Medical Technology Assessment, Rotterdam, Netherlands; 2 University Medical Center Utrecht, Utrecht, Netherlands; 3 University Medical Centre st Radboud Nijmegen; 4 Reinier de Graaf Group, Delft; 5 Eli Lilly, The Netherlands

PMH15

ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN SWEDEN
Myren KJ1, Gillberg C2, Nydén A2
1 Eli Lilly Sweden AB, Solna, Sweden; 2 Göteborg University, Gothenburg, Sweden

PMH16

Withdrawn

PMH17

COST-UTILITY ANALYSIS OF MEDICAL CO-PRESCRIPTION OF HEROIN COMPARED WITH METHADONE MAINTENANCE TREATMENT FOR CHRONIC, TREATMENT RESISTANT HEROIN ADDICTS
Dijkgraaf MGW1, Van der Zanden BP1, De Borgie CAJM1, Blanken P2, Van Ree JM2, Van den Brink W1
1 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands; 2 University Medical Centre Utrecht, Utretch, Germany

PMH30

COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION
Crowley S1, Schrover R1, Neville AM2
1 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia; 2 Pretium, Sydney, NSW, Australia

 

Quality of Life/Utility/Preference Studies

PMH18

ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A: AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL STUDIES
Dickson M1, Kozma C2, Barron R3
1 University of South Carolina, Columbia, SC, USA; 2 Independent Outcomes Consultant, West Columbia, SC, USA; 3 Allergan Pharmaceuticals, Irvine, CA, USA

PMH19

THE PERCEIVED BENEFITS OF DOSING SCHEDULES FOR CHILDREN WITH ADHD
Price M1, Lloyd A2, Yuen C1, Dewilde S2, Annemans L3, Coghill D4
1 Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 2 MEDTAP International, London, UK; 3 HEDM, Meise, Belgium; 4 University of Dundee, UK

PMH20

PATIENT-REPORTED OUTCOMES: DO THEY AGREE WITH OBJECTIVE CAREGIVER-REPORTED OUTCOMES FOR INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY?
Barr J, Schumacher G, Ohman S, Mason E
Northeastern University, Boston, MA, USA

PMH21

IS HEALTH-RELATED QUALITY OF LIFE EVALUATION DIFFERENT BETWEEN CLINICAL TRIALS AND OBSERVATIONAL STUDIES IN MAJOR DEPRESSIVE DISORDER?
Sapin C, Le Lay A, Francois C
H. Lundbeck A/S, Paris, France


Health Policy Studies

PMH22

Withdrawn

PMH23

ADHD TREATMENT AND CO-MORBIDITIES: BASELINE RESULTS FROM THE OBSERVATIONAL STUDY ADORE IN GERMANY
Rothenberger A1, Döpfner M2, Finnern H3, Lorenzo M4, Ralston S4, Dittmann R3
1 Georg-August-University Göttingen, Göttingen, Germany; 2 University of Cologne, Cologne, Germany; 3 Lilly Deutschland GmbH, Bad Homburg, Germany; 4 Eli Lilly and Company Ltd, Windlesham, UK

PMH24

EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA
Joyce AT1, Ollendorf DA1, Harrison DJ2, Cheli A2
1 PharMetrics Inc, Watertown, MA, USA; 2 Pfizer Inc, New York, NY, USA

PMH25

EMERGENCY DEPARTMENTS: THE FRONT LINE OF SCHIZOPHRENIA MANAGEMENT?
O'Brien JA, Pitoniak-Morse C, Duran P, Caro JJ
Caro Research Institute, Concord, MA, USA

PMH26

SSRI UTILIZATION AND PERSISTENCE IN A CALIFORNIA MEDICAID POPULATION
Nichol MB1, Shi SG1, Knight TK1, Popovian R2
1 University of Southern California, Los Angeles, CA, USA; 2 Pfizer, Inc, New York, NY, USA

PMH27

THE EFFECT OF RAISING THREE TIER CO-PAYMENTS ON SSRI ANTIDEPRESSANT COMPLIANCE RATES
Mark TL1, Bron M2
1 Medstat, Washington, DC, USA; 2 Pfizer, Inc, New York, NY, USA


Methods

PMH28

METABOLIC OUTCOMES OF ANTIPSYCHOTICS IN SCHIZOPHRENIA: A MARKOV MODEL
Sorensen SV1, Leaderer M2, Harrison DJ2, Prasad M1, Hollenbeak CS1, Revicki D1, Dugar A2, Cheli A2, Remák E3
1 MEDTAP International Inc, Bethesda, MD, USA; 2 Pfizer Inc, New York, NY, USA; 3 MEDTAP International Inc, London, UK

 

MEN’S & WOMEN’S HEALTH

 

Cost Studies

PMW1

ECONOMIC EVALUATION OF THE ADMINISTRATION OF FOLLITROPIN-Â WITH A PEN DEVICE COMPARED WITH ADMINISTRATION OF MENOTROPIN BY CONVENTIONAL SYRINGE
Bruijnesteijn K1, Van Genugten ML1, Hoomans E2, Limbourg M3, Van Loon J1
1 Mapi Values, Houten, Netherlands; 2 Organon Nederlands BV, Oss, Noord Brabant, Netherlands; 3 Organon Belgium, Brussels, Belgium

PMW2

HOW MUCH DOES UNINTENDED PREGNANCY COST THE UK HEALTH CARE SYSTEM?
Sonnenberg F1, Price M2, Neslusan C3
1 UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2 Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 3 Johnson & Johnson Pharmaceutical Services, New Brunswick, NJ, USA

PMW3

IMPROVING THE DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING: COSTS AND BARRIERS TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO MOTHER-BABY PACKAGE IN MORELOS, MEXICO
Cahuana L1, Sosa S2, Bertozzi S1
1 National Institute of Public Health, Cuernavaca, Morelos, Mexico; 2 University of York, Heslington, York, UK


Quality of Life/Utility/Preference Studies

PMW4

VALIDATION OF THE SPANISH VERSION OF THE SELF-ESTEEM AND RELATIONSHIP (SEAR) QUESTIONNAIRE FOR MEN WITH ERECTILE DYSFUNCTION (ED)
Rejas J1, Cabello F2, Calle A3, Chantada V4, Forà F5, Garcia-Garcia M6, Rico-Villademoros F7, Martínez-Sánchez EM1
1 Pfizer SA, Alcobendas, Madrid, Spain; 2 Instituto Andaluz de Sexología, Málaga, Spain; 3 Hospital Clínico San Carlos, Madrid, Spain; 4 Hospital Juan Canalejo, La Coruña, Spain; 5 Centro Médico Teknon, Barcelona, Spain; 6 Biométrica CRO, Barcelona, Spain; 7 Biométrica CRO, Madrid, Spain

PMW5

INFERTILITY TREATMENT POLICIES IN GERMANY AND THE UK - WILLINGNESS TO PAY AMONG AFFECTED COUPLES
Kilgert K, Smala A, Berger K
MERG Medical Economics Research Group, München, Germany

PMW6

SHORT-TERM AND LONG-TERM PSYCHOSOCIAL CONSEQUENCES OF FALSE POSITIVE SCREENING MAMMOGRAPHY – DEVELOPMENT OF TWO NEW QUESTIONNAIRE BASED ON THE PSYCHOLOGICAL CONSEQUENCES QUESTIONNAIRE (THE PCQ)
Brodersen J, Thorsen H, Andersen JS
Copenhagen University, Copenhagen, Denmark

 

NEUROLOGICAL DISORDERS

 

Clinical Outcomes Studies

PNL1

PREVALENCE, HEALTH RESOURCES USAGE AND COST OF VASCULAR DEMENTIA IN COMPARISON WITH ALZHEIMER DISEASE IN A POPULATION SETTING IN SPAIN
Sicras A1, Rejas J2, Arco S3, Flores E4, Ortega G5, Esparcia A5, Suárez A3, Gordillo MJ4
1 Badalona Gestió Assistencial, SL, Badalona, Barcelona, Spain; 2 Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain; 3 Area Básica de Salud Apenins-Montigalà, Badalona, Barcelona, Spain; 4 Area Básica de Salud Morera-Pomar, Badalona, Barcelona, Spain; 5 Area Básica de Salud Tiana-Montgat, Montgat, Barcelona, Spain

PNL2

STROKE SEVERITY AND EARLY OUTCOMES AFTER FIRST-EVER ISCHEMIC STROKE
Tseng MC1, Chang KC2
1 National Sun Yat-Sen University, Kaohsiung, Taiwan; 2 Chang Gung Memorial Hospital, Kaohsiung, Taiwan


Cost Studies

PNL3

PREDICTORS FOR DIRECT AND INDIRECT COSTS IN PARKINSON’S DISEASE
Siebert U1, Bornschein B2, Spottke EA3, Berger K4, Oertel WH5, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 University of Bonn, Bonn, Germany; 4 MERG Medical Economics Research Group, Munich, Germany; 5 University of Marburg, Marburg, Germany

PNL4

NEW LEVODOPA/CARBIDOPA/ENTACAPONE (STALEVO®) RESULTS IN BETTER QUALITY OF LIFE FOR PARKINSON´S DISEASE PATIENTS AND SAVES COSTS TO THE SOCIETY
Findley L1, Turunen H2, Apajasalo M2, Lees A3
1 Oldchurch Hospital, Essex, UK; 2 Orion Pharma, Espoo, Finland; 3 Reta Lila Weston Institute of Neurological Studies, London, UK

PNL5

SOCIAL COSTS OF PARKINSON DISEASE IN ITALY
Zecchinelli A1, Caprari F2, Ponzi P2, Bonetti A1, Pezzoli G1
1 Istituti Clinici di Perfezionamento, Milano, Italy; 2 Fondazione Medtronic Italia, Milano, Italy

PNL6

THE HOSPITAL COSTS OF PRIMARY STROKE PATIENTS MANAGEMENT IN POLAND
Niewada M1, Czonkowska A2, Czonkowski A1, £atek M3, Kamiñski B3
1 Medical University of Warsaw, Warsaw, Poland; 2 Institute of Psychiatry and Neurology, Warsaw, Poland; 3 Warsaw School of Economics, Warsaw, Poland

PNL7

COSTS OF STROKE UNIT CARE IN GERMANY
Back T1, Haacke C2, Spottke EA3, Schöffski O4, Dodel R3
1 Marburg University, Marburg, Germany; 2 University of Marburg; 3 Friedrich-Wilhelms-University, Bonn, Germany; 4 University of Erlangen

PNL8

COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC STROKE IN TAIWAN
Tseng MC1, Chang KC2
1 National Sun Yat-Sen University, Kaohsiung, Taiwan; 2 Chang Gung Memorial Hospital, Kaohsiung, Taiwan

PNL9

INDIRECT COSTS ASSOCIATED TO INSOMNIA IN OCCUPATIONAL HEALTH: THE SISYPHE STUDY
Godet-Cayré V1, Pelletier-Fleury N1, Leger D2, Dinet J3, Massuel MA3
1 INSERM, Le Kremlin-Bicêtre, France; 2 Centre de Sommeil Hôtel Dieu de Paris, Paris, France; 3 Sanofi-Synthelabo France, Le Plessis Robinson, France

PNL10

THE SOCIOECONOMIC IMPACT OF NARCOLEPSY
Dodel R1, Peter H2, Walbert T3, Spottke EA1, Berger K4, Siebert U5, Kesper K6, Becker H6, Mayer G7
1 Friedrich-Wilhelms-University, Bonn, Germany; 2 Philipps University, Marburg, Germany; 3 University of Bonn, Bonn, Germany; 4 MERG Medical Economics Research Group, München, Germany; 5 Harvard Medical School, Boston, MA, USA; 6 Marburg University, Marburg, Germany; 7 Hephata Kliniken, Schwalmstadt-Treysa, Germany

PNL11

EFFECT OF COMORBIDITIES ON MEDICAL CARE USE AND COST AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER
Lee WC1, Arcona S2, Thomas SK2, Wang Q1, Hoffmann MS1, Botteman MF1, Pashos CL3
1 Abt Associates Inc, Bethesda, MD, USA; 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3 Abt Associates Inc, Cambridge, MA, USA

PNL12

HEALTHCARE UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES
Spottke EA1, Mylius V2, Claus D3, Grothe C1, Heuss D4, Kiefer R5, Klockgether T1, Schrank B6, Schröder R1, Vielhaber S7, Walbert T1, Dodel R1, Schepelmann K2
1 Friedrich-Wilhelms-University, Bonn, Germany; 2 Philipps-University, Marburg, Germany; 3 Clinic Darmstadt, Darmstadt, Germany; 4 University Erlangen, Erlangen, Germany; 5 University Muenster, Muenster, Germany; 6 Clinic of Diagnostics, Wiesbaden, Germany; 7 Otto-von-Guericke University, Magdeburg, Germany

PNL13

PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE
Maurel F1, Girard B1, Crochard A2, Henri M2, El Hasnaoui A2, Le Pen C3
1 Aremis Consultants, Paris, France; 2 GlaxosmithKline, France; 3 Aremis Consultants and Paris Dauphine University, Paris, France

PNL14

THE COST-EFFECTIVENESS OF TREATING PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) USING ROPINIROLE
Moore AP1, Lloyd A2, Scott DA2, Connolly M3, Dixon S4
1 The Walton Centre for Neurology and Neurosurgery, Liverpool, UK; 2 Fourth Hurdle; 3 GlaxoSmithKline, London, Middlesex, UK; 4 Sheffield University, Sheffield, South Yorkshire, UK

PNL15

RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORTÒ AND BOTOXÒ IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM – THE REAL DOSE STUDY EXPANSION – COST CONSIDERATIONS BASED ON DRUG START
Magar R1, Ahmed F2, Findley L3, Larsen JP4, Pirtosek Z5, Slawek J6, Rùžièka E7
1 Thomson Corporation, Secaucus, NJ, USA; 2 Hull Royal Infirmary, UK; 3 Essex Neuroscience Unit, UK; 4 Central Hospital of Rogaland, Norway; 5 University Clinical Centre, Slovenia; 6 St. Adalbert Hospital, Poland; 7 Charles University, Czech Republic

PNL16

A COMPARATIVE STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSON'S DISEASE (PD) PATIENTS
Roch B1, Despiegel N2, François C1, Goren T3
1 H. Lundbeck A/S, Paris, France; 2 H.Lundbeck A/S, Paris, France; 3 Teva Pharmaceuticals, Petach Tikva, Israel

PNL17

MARKOV MODEL OF ADJUNCTIVE ANTIEPILEPTIC TREATMENT FOR CHILDREN - A COMPARISON OF TOPIRAMATE AND LAMOTRIGINE
Remák E1, Hutton J1, Price M2, Peeters K3, Adriaenssen I3
1 MEDTAP International Inc, London, UK; 2 Janssen-Cilag, High Wycombe, UK; 3 Johnson & Johnson Pharmaceutical Services, Beerse, Belgium

PNL18

COSTS AND OUTCOMES ASSOCIATED WITH THE USE OF BOTULINUM TOXIN TYPE A (BTX-A) IN THE TREATMENT OF FLEXED WRIST/CLENCHED FIST POST-STROKE SPASTICITY
Christensen TL1, Poulsen PB1, Holmström S2
1 Muusmann Research & Consulting, Kolding, Denmark; 2 Allergan R&D Europe, Mougins-Cedex, France

PNL31

HEALTHCARE RESOURCES USED BY SPANISH PRIMARY CARE PHYSICIANS IN PATIENTS WITH SUBJECTIVE MEMORY COMPLAINTS OR COGNITIVE IMPAIRMENT. THE ISSEA STUDY
Badia X1, Argimón JM2, Martínez-Lage JM3, Riu S4, Lara N1
1 Health Outcomes Research Europe Group, Barcelona, Spain; 2 Regió Sanitària Costa de Ponent.Catsalut; 3 Unidad de Transtornos de Memoria. Clínica Universitaria de Navarra, Pamplona, Spain; 4 Unitat de Psicogeriatria. Centre geriàtric, Llars Mundet, Barcelona, Spain


Quality of Life/Utility/Preference Studies

PNL19

VALIDATING THE RESTLESS LEGS SYNDROME QUALITY OF LIFE QUESTIONNAIRE (RLSQOL) IN A TRIAL PATIENT POPULATION
Abetz L1, Arbuckle R2, Allen R3, Mavraki E4, Kirsch J4
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2 Mapi Values Ltd; 3 Johns Hopkins Bayview Medical Center, Baltimore, MD, USA; 4 GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA

PNL20

A SIMPLIFIED SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME : THE DESYR STUDY GROUP
Montplaisir J1, Crochard A2, Arnulf I3, Huas D4, Krieger J5, Lainey E6, Leger D7, Pouchain D2, Tison F8, Schwalm M9, Schuck S10, El Hasnaoui A2
1 Hopital du Sacré-Coeur, Montreal, QC, Canada; 2 GlaxoSmithKline, Les Ulis, France; 3 Hopital de la Pitié-Salpétrière, Paris, France; 4 Université Xavier Bichat, Paris, France; 5 Université Louis Pasteur, Strasbourg, France; 6 Hopital européen Georges Pompidou, Paris, France; 7 Hotel dieu, Paris, France; 8 Université de Bordeaux 1, Talence, France; 9 BKL Thalès, Paris, France; 10 Kappa Santé, Paris, France

PNL21

INDEPENDENT EFFECT OF DYSKINESIA ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON’S DISEASE – A MULTIVARIATE ANALYSIS
Siebert U1, Bornschein B2, Dodel R3, Competence Network Parkinson Syndromes C4
1 Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 University of Bonn, Bonn, Germany; 4 University of Marburg, Marburg, Germany

PNL22

EFFECT OF DISEASE-SPECIFIC COMPLICATIONS ON THE PREDICTION OF UTILITIES IN PARKINSON’S DISEASE
Siebert U1, Bornschein B2, Spottke EA3, Dodel R3
1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 University of Bonn, Bonn, Germany

PNL23

CHRONIC NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT QUALITY OF LIFE AND DISABILITY: RESULTS FROM THE DONEGA STUDY
Gálvez R1, Ribera MV2, Rejas J3, Masramón X4, Ruíz M3
1 Pain & Palliative Care Unit, Hospital Virgen de las Nieves, Granada, Spain; 2 Pain Unit, Hospital Vall d´Hebrón, Barcelona, Spain; 3 Pfizer SA, Alcobendas, Madrid, Spain; 4 Euroclin Institute, Barcelona, Spain

PNL31

NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT MENTAL FUNCTIONING, SYMPTOM LEVELS OF ANXIETY AND DEPRESSION, AND SLEEP DISTURBANCE: RESULTS FROM THE DONEGA STUDY

Gálvez R1, Ribera MV2, Rejas J3, Masramón X4, Ruíz M3
1 Pain & Palliative Care Unit, Hospital Virgen de las Nieves, Granada, Spain; 2 Pain Unit, Hospital Vall d´Hebrón, Barcelona, Spain; 3 Pfizer SA, Alcobendas, Madrid, Spain; 4 Euroclin Institute, Barcelona, Spain

Health Policy Studies

PNL24

COMPARING CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE REGRESSION FOR TRANSLATING A CLINICAL PARKINSON'S DISEASE SCALE INTO UTILITIES
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 University of Bonn, Bonn, Germany

PNL25

INTERNAL, EXTERNAL, AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 Friedrich-Wilhelms-University, Bonn, Germany

PNL26

A NEW SCREENING TOOL FOR MIGRAINE IN THE GENERAL POPULATION: THE MIGRAINE-SCREEN-Q (MS-Q)
Láinez JM1, Domínguez M2, Arriaza E3, Palacios G3, Madrigal M3, Garcia-Garcia M4, Rejas J3
1 University Hospital, Valencia, Spain; 2 Hospital Puerta de Hierro, Madrid, Spain; 3 Pfizer SA, Alcobendas, Madrid, Spain; 4 Biométrica CRO, Barcelona, Spain

PNL27

MAPPING THE INTERNATIONAL RESTLESS LEGS SYNDROME RATING SCALE (IRLS) TO THE EQ-5D BY FOUR CLINICIANS
Loftus JV1, Connolly M1, Allen R2, Garcia-Borreguero D3, Billiard M4, Tidswell P5
1 GlaxoSmithKline, London, Middlesex, UK; 2 Neurology and Sleep Medicine, Baltimore, MD, USA; 3 Fundacion Jiminez Diaz, Madrid, Spain; 4 Gui de Chauliac, Montpelier, Cedex 5, France; 5 Chorley Clinic Research Centre, Chorley, Lancashire, UK

PNL28

CENTERED REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND TRANSFERABILITY OF MARKOV MODELS
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2 University of Munich, Munich, Germany; 3 University of Bonn, Bonn, Germany

PNL29

ESTIMATING THE COST OF ILLNESS IN EUROPE – A MODEL WITH MULTIPLE SCLEROSIS AS AN EXAMPLE
Andlin-Sobocki P1, Kobelt G2, Pugliatti M3, Jönsson B4
1 Karolinska Institute, Stockholm, Sweden; 2 European Health Economics SAS, Spéracèdes, France; 3 University of Sassari, Sassari, Italy; 4 Center for Health Economics, Stockholm School of Economics, Stockholm, Sweden

 

PITUITARY GLAND DISORDERS

 

Cost Studies

PPT1

COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY
Didoni G1, Ghigo E2, Minuto F3
1 Pfizer Italia srl, Rome, Italy; 2 Molinette Hospital, Turin, Italy; 3 University of Genoa, Genoa, Italy

Quality of Life/Utility/Preference Studies

PPT2

THE DEFICIT IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND & WALES: A COMPARISON WITH NORMATIVE POPULATION DATA
Mattsson A1, Casanueva F2, Espadero R3, Bada X4, Sanmarti A5, Kind P6, Koltowska-Häggström M1
1 Pfizer Health AB, Stockholm, Sweden; 2 University of Santiago de Compostela, Santiago de Compostela, Spain; 3 Pfizer, Madrid, Spain; 4 Health Outcomes Research Europe, Barcelona, Spain; 5 Hospital Germans Trias i Pujol, Badalona, Spain; 6 University of York, York, UK

 

URINARY/KIDNEY DISEASES DISORDERS

 

Cost Studies

PUK1

THE COST-EFFECTIVENESS OF EXTENDED RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN GERMANY AND THE UNITED KINGDOM
Anderson P1, Resch A2, Dooley JA3, Bruggenjurgen B4, Zlateva G5
1 Fourth Hurdle Consulting Ltd, London, UK; 2 Pfizer GmBH, Karlsruhe, Germany; 3 Pfizer Ltd, Tadworth, UK; 4 Alpha Care GmbH, Celle, Germany; 5 Pfizer, Inc, New York, NY, USA

PUK2

COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN
Castro D1, Soto J2, Exposito I2
1 Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; 2 Pfizer S.A, Alcobendas, Madrid, Spain

PUK3

ECONOMIC ASSESSMENT OF URO-VAXOM® IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY
Brüggenjürgen B1, Cozma G2
1 Alpha Care GmbH, Celle, Germany; 2 OM PHARMA, Meyrin, Switzerland

PUK4

PATIENT PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS HEALTHCARE RESOURCE USE
Cerulli A1, Kahler K1, Banfe E2, Gause D1
1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2 Consumer Health Sciences, Princeton, NJ, USA

PUK5

ECONOMIC VALUATION OF THE EFFECTS OF DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF CHRONIC RENAL DISEASE
Di Stasi F1, Monzini MS1, Colasanti G2, Luperini M2, Arrigo G2, Mantovani LG1
1 University of Milan, Milan, Italy; 2 Azienda Ospedaliera “Ospedale S. Carlo Borromeo”, Milan, Italy

PUK6

COST OF RENAL TRANSPLANTATION IN BELGIUM
Lecomte P1, Chaib Eddour D2, Squifflet JP2
1 Novartis Pharma, Vilvoorde, Brussels, Belgium; 2 Cliniques UCL Saint-Luc, Brussels, Belgium

PUK7

WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?
Kuehne FC1, Stoffel MP2, Barth C3, Baldamus CA4
1 PharmacoConsult, Wanzleben, Germany; 2 KfH, Cologne, Germany; 3 KfH, Neu-Isenburg, Germany; 4 University Cologne, Cologne, Germany

PUK8

2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
Hagenmeyer EG1, Häussler B1, Balshaw R2, Keown P3, Kilburg A4, Kaló Z5, Nashan B6
1 IGES Institut für Gesundheits- u. Sozialforschung, Berlin, Germany; 2 Simon Fraser University and Syreon Corp; 3 Department of Medicine, University of British Columbia; 4 Novartis Pharma AG; 5 Novartis Hungary Ltd; 6 Dalhousie University Halifax

PUK9

EVALUATION OF THE COST UTILITY OF SIROLIMUS VERSUS TACROLIMUS FOR IMMUNOSUPPRESSION FOR RENAL TRANSPLANTATION IN THE UK
Currie CJ1, Dixon S2, Conway P3, McEwan P4
1 Cardiff Research Consortium, Cardiff, Wales, UK; 2 Sheffield University, Sheffield, South Yorkshire, UK; 3 Wyeth UK, Maidenhead, UK; 4 Cardiff University, Cardiff, Wales, UK

PUK10

A HEALTH ECONOMIC EVALUATION OF 6 MONTHS ALFUZOSIN TREATMENT IN THE MANAGEMENT OF ACUTE URINARY RETENTION
Lamotte M, Cleemput I, Annemans L
HEDM, Meise, Belgium

PUK11

COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE STATUTORY HEALTH INSURANCE IN GERMANY
Papanicolaou S1, Andlin-Sobocki P2, Thüroff J3, Graf v.d. Schulenburg J-M4, Blanke M4, Finnern H5, Sykes D1
1 Eli Lilly and Company Ltd, Windlesham, Surrey, UK; 2 Stockholm Health Economics AB, Stockholm, Sweden; 3 Johannes Gutenberg University Mainz, Mainz, Germany; 4 University of Hannover, Hannover, Germany; 5 Lilly Deutschland GmbH, Bad Homburg, Germany

PUK12

LONG-TERM COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS
Hjelmgren J1, Malmberg L2, Ragnarson-Tennvall G1
1 The Swedish Institute for Health Economics (IHE), Lund, Sweden; 2 Lund University Hospital, Lund, Sweden


Quality of Life/Utility/Preference Studies

PUK13

LOWER MENTAL HEALTH SCORES MEASURED USING THE SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT THERAPY
García-Mendoza M, Valdés C, Rebollo P, Ortega T, Ortega F
Hospital Universitario Central de Asturias Institute, Oviedo, Spain

PUK14

ELDERLY PATIENTS STARTING RENAL REPLACEMENT THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING THE FIRST TWO YEARS
García-Mendoza M, Valdés C, Ortega T, Rebollo P, Ortega F
Hospital Universitario Central de Asturias Institute, Oviedo, Spain

PUK15

PATIENTS UNDERGOING PERITONEAL DIÁLISIS HAVE BETTER PERCEIVED HEALTH IN SEVERAL SPECIFIC PROBLEMS RELATED WITH RENAL DISEASE THAN PATIENTS UNDERGOING HEMODIALYSIS
Valdés C1, Alvarez-Ude F2, Rebollo P1, Estebanez C2
1 Hospital Universitario Central de Asturias Institute, Oviedo, Spain; 2 Hospital General de Segovia Instutute, Segovia, Spain

PUK16

VALIDATION OF TWO QUESTIONNAIRES ON SYMPTOMS AND QUALITY OF LIFE IN ITALIAN WOMEN WITH LUTS: THE FLOW STUDY
Simoni L1, Rizzi CA2, Santini A2, Sgarbi S1, Tubaro A3, Prezioso D4, Zattoni F5, Artibani W6, Pesce F6, Scarpa RM7
1 MediData srl, Modena, Italy; 2 Boehringer Ingelheim, Milan, Italy; 3 Hospital S. Andrea, Roma, Italy; 4 University “Federico II”, Naples, Italy; 5 Az Osp S.M. Misericordia, Udine, Italy; 6 Policlinico G. Rossi, Verona, Italy; 7 University of Torino, Turin, Italy

PUK17

EVALUATION OF TREATMENT OF FEMALE URINARY INCONTINENCE WITH THE ICIQ-UI SF QUESTIONNAIRE
Espuña M1, Rebollo P2, Puig M1
1 Hospital Clinic i Provincial. Universidad de Barcelona, Barcelona, Catalonia, Spain; 2 Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

PUK18

VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE ACTIVITY IMPAIRMENT AS A RESULT OF UNCOMPLICATED URINARY TRACT INFECTION: THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA)
Wild DJ1, Clayson DJ1, Keating K2, Gondek K2
1 Oxford Outcomes Ltd, Oxford, Oxon, UK; 2 Bayer HealthCare Pharmaceuticals, West Haven, CT, USA

PUK19

DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTRES
Oppe M, Weijnen TJG, de Charro FT
Erasmus University Rotterdam, Rotterdam, Netherlands

PUK24

PREVALENCE AND QUALITY OF LIFE IN FRENCH WOMEN WITH STRESS URINARY INCONTINENCE

Gasquet I1, Klein P2, Gaudebout P3, Alfonsi A4, Tcherny S4, Haab F5
1 Paul Brousse Hospital - AP-HP, Villejuif, France; 2 IPSOS, Paris, France; 3 AP-HP, Paris, France; 4 LILLY France, Suresnes, France; 5 Tenon Hospital, Paris, France


Health Policy Studies

PUK20

IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION
Nitz NM1, Jumadilova Z2, Meyer J1, Bavendam T2
1 Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 2 Pfizer, Inc, New York, NY, USA

PUK21

AN ANALYSIS OF PATIENTS ON WAITING LISTS TO RECEIVE SURGERY FOR STRESS URINARY INCONTINENCE (SUI) IN ENGLAND AND SCOTLAND
McAllister R1, Das Gupta R2, Piercy J3, Ryan J1
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2 Boehringer-Ingelheim, Bracknell, UK; 3 Adelphi Group, UK


Methods

PUK22

DERIVING UNIT COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE) - AN OBSERVATIONAL STUDY IN 14 EUROPEAN COUNTRIES
Papanicolaou S1, Davies A2, Espuña-Pons M3, Hampel C4, Hunskaar S5, Monz B6, Samsioe G7, Wagg A8, Sykes D9
1 Eli Lilly and Company Limited, Windlesham, Surrey, UK; 2 MEDTAP International, London, UK; 3 University Hospital of Barcelona, Spain; 4 University Hospital of Mainz, Germany; 5 University of Bergen, Norway; 6 Boehringer Ingelheim GmbH, Ingelheim, Germany; 7 Lunds University Hospital, Sweden; 8 University College Hospital, London, UK; 9 Eli Lilly and Company Limited, Windlesham, UK

PUK23

LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA: DEVELOPMENT OF A COST-EFFECTIVENESS MODEL
Brennan A, Akehurst R, Davis S, Sakai H
School of Health and Related Research, University of Sheffield, Sheffield, UK

 


7th Annual European Congress Main Page

 

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.